Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

2.

Polygenic link between blood lipids and amyotrophic lateral sclerosis.

Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F.

Neurobiol Aging. 2018 Jul;67:202.e1-202.e6. doi: 10.1016/j.neurobiolaging.2018.03.022. Epub 2018 Mar 27.

PMID:
29685649
3.

Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients.

Checa A, Malmqvist A, Flyckt L, Schwieler L, Samuelsson M, Skogh E, Cervenka S, Dahl ML, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Erhardt S, Wheelock CE.

Schizophr Res. 2018 Apr 4. pii: S0920-9964(18)30181-6. doi: 10.1016/j.schres.2018.03.029. [Epub ahead of print] No abstract available.

PMID:
29627172
4.

Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures.

Günther M, Al Nimer F, Piehl F, Risling M, Mathiesen T.

eNeuro. 2018 Mar 19;5(2). pii: ENEURO.0335-17.2018. doi: 10.1523/ENEURO.0335-17.2018. eCollection 2018 Mar-Apr.

5.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.

Piehl F, Hillert J.

Mult Scler. 2018 Aug;24(9):1157-1159. doi: 10.1177/1352458518757930. Epub 2018 Feb 22. No abstract available.

PMID:
29468952
6.

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.

Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 May;74(5):663-670. doi: 10.1007/s00228-018-2429-1. Epub 2018 Feb 10.

7.

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.

Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum IS, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M.

Front Neurol. 2017 Dec 13;8:675. doi: 10.3389/fneur.2017.00675. eCollection 2017.

8.

Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients.

James T, Lindén M, Morikawa H, Fernandes SJ, Ruhrmann S, Huss M, Brandi M, Piehl F, Jagodic M, Tegnér J, Khademi M, Olsson T, Gomez-Cabrero D, Kockum I.

Hum Mol Genet. 2018 Mar 1;27(5):912-928. doi: 10.1093/hmg/ddy001.

PMID:
29325110
9.

Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers.

Brenner P, Granqvist M, Königsson J, Al Nimer F, Piehl F, Jokinen J.

Psychoneuroendocrinology. 2018 Mar;89:53-58. doi: 10.1016/j.psyneuen.2018.01.002. Epub 2018 Jan 4.

PMID:
29324301
10.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

PMID:
29309484
11.

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study.

Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 Feb;74(2):219-226. doi: 10.1007/s00228-017-2366-4. Epub 2017 Nov 11.

12.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

13.

Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis.

Varade J, Wang N, Lim CK, Zhang T, Zhang Y, Liu X, Piehl F, Matell R, Cao H, Xu X, Hammarström L.

J Autoimmun. 2018 Mar;88:43-49. doi: 10.1016/j.jaut.2017.10.002. Epub 2017 Oct 14.

PMID:
29037440
14.

Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.

Sveinsson O, Granqvist M, Forslin Y, Blennow K, Zetterberg H, Piehl F.

J Neuroimmunol. 2017 Nov 15;312:15-18. doi: 10.1016/j.jneuroim.2017.08.011. Epub 2017 Aug 25.

PMID:
28886955
15.

Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.

Ruhrmann S, Ewing E, Piket E, Kular L, Cetrulo Lorenzi JC, Fernandes SJ, Morikawa H, Aeinehband S, Sayols-Baixeras S, Aslibekyan S, Absher DM, Arnett DK, Tegner J, Gomez-Cabrero D, Piehl F, Jagodic M.

Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356. [Epub ahead of print]

PMID:
28766461
16.

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.

Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A.

Mult Scler. 2018 Aug;24(9):1224-1233. doi: 10.1177/1352458517720044. Epub 2017 Aug 1.

PMID:
28762877
17.

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis.

Longinetti E, Mariosa D, Larsson H, Ye W, Ingre C, Almqvist C, Lichtenstein P, Piehl F, Fang F.

Neurology. 2017 Aug 8;89(6):578-585. doi: 10.1212/WNL.0000000000004179. Epub 2017 Jul 12.

18.

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.

Spelman T, Frisell T, Piehl F, Hillert J.

Mult Scler. 2018 Jul;24(8):1087-1095. doi: 10.1177/1352458517713668. Epub 2017 Jun 26.

PMID:
28649912
19.

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.

Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T.

Mult Scler. 2018 Jul;24(8):1046-1054. doi: 10.1177/1352458517715132. Epub 2017 Jun 19.

PMID:
28627962
20.

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis.

Simonsen CS, Hansen G, Piehl F, Edland A.

Mult Scler J Exp Transl Clin. 2016 Jul 12;2:2055217316658304. doi: 10.1177/2055217316658304. eCollection 2016 Jan-Dec.

21.

Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.

Jonsson DI, Pirskanen R, Piehl F.

Neuromuscul Disord. 2017 Jun;27(6):565-568. doi: 10.1016/j.nmd.2017.03.007. Epub 2017 Mar 16.

PMID:
28433474
22.

A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis.

Kannan V, Kiani NA, Piehl F, Tegner J.

Math Biosci. 2017 Jul;289:1-8. doi: 10.1016/j.mbs.2017.03.006. Epub 2017 Mar 29.

23.

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE.

Mult Scler. 2018 Apr;24(4):472-480. doi: 10.1177/1352458517699874. Epub 2017 Mar 15.

24.

CSF GABA is reduced in first-episode psychosis and associates to symptom severity.

Orhan F, Fatouros-Bergman H, Goiny M, Malmqvist A, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Cervenka S, Collste K, Victorsson P, Sellgren CM, Flyckt L, Erhardt S, Engberg G.

Mol Psychiatry. 2018 May;23(5):1244-1250. doi: 10.1038/mp.2017.25. Epub 2017 Mar 14.

25.

Population-based incidence and clinical characteristics of idiopathic intracranial hypertension.

Sundholm A, Burkill S, Sveinsson O, Piehl F, Bahmanyar S, Nilsson Remahl AIM.

Acta Neurol Scand. 2017 Nov;136(5):427-433. doi: 10.1111/ane.12742. Epub 2017 Feb 28.

PMID:
28244170
26.

Multiple Sclerosis-A Tuning Fork Still Required.

Piehl F.

JAMA Neurol. 2017 Mar 1;74(3):264-265. doi: 10.1001/jamaneurol.2016.5126. No abstract available.

PMID:
28114595
27.

Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.

Sundgren M, Piehl F, Wahlin Å, Brismar T.

Mult Scler Relat Disord. 2016 Nov;10:36-43. doi: 10.1016/j.msard.2016.08.011. Epub 2016 Aug 24.

PMID:
27919496
28.

Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis - a case report.

Håkansson I, Sandstedt A, Lundin F, Askmark H, Pirskanen R, Carlson K, Piehl F, Hägglund H.

Neuromuscul Disord. 2017 Jan;27(1):90-93. doi: 10.1016/j.nmd.2016.09.020. Epub 2016 Sep 28.

PMID:
27863874
29.

Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases.

Yau AC, Piehl F, Olsson T, Holmdahl R.

Immunology. 2017 Apr;150(4):408-417. doi: 10.1111/imm.12692. Epub 2016 Dec 22.

30.

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J.

J Neurochem. 2017 Apr;141(2):296-304. doi: 10.1111/jnc.13881. Epub 2016 Nov 29.

31.

Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Toll-like Receptor Stimulation in Peripheral Monocytes.

Orhan F, Bhat M, Sandberg K, Ståhl S, Piehl F; Karolinska Schizophrenia Project (KaSP) consortium, Svensson C, Erhardt S, Schwieler L.

Scand J Immunol. 2016 Nov;84(5):262-271. doi: 10.1111/sji.12479.

32.

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A.

Neurology. 2016 Nov 15;87(20):2074-2081. Epub 2016 Oct 19.

33.

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions.

Brenner P, Piehl F.

Acta Neurol Scand. 2016 Sep;134 Suppl 200:47-54. doi: 10.1111/ane.12648. Review.

PMID:
27580906
34.

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Vågberg M, Axelsson M, Birgander R, Burman J, Cananau C, Forslin Y, Granberg T, Gunnarsson M, von Heijne A, Jönsson L, Karrenbauer VD, Larsson EM, Lindqvist T, Lycke J, Lönn L, Mentesidou E, Müller S, Nilsson P, Piehl F, Svenningsson A, Vrethem M, Wikström J.

Acta Neurol Scand. 2017 Jan;135(1):17-24. doi: 10.1111/ane.12667. Epub 2016 Aug 24. Review.

35.

Reply.

Alping P, Frisell T, Svenningsson A, Piehl F.

Ann Neurol. 2016 Nov;80(5):791-792. doi: 10.1002/ana.24767. Epub 2016 Sep 27. No abstract available.

PMID:
27553863
36.

Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.

Lam MA, Maghzal GJ, Khademi M, Piehl F, Ratzer R, Romme Christensen J, Sellebjerg FT, Olsson T, Stocker R.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. doi: 10.1212/NXI.0000000000000256. eCollection 2016 Aug.

37.

T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis.

Öckinger J, Hagemann-Jensen M, Kullberg S, Engvall B, Eklund A, Grunewald J, Piehl F, Olsson T, Wahlström J.

Clin Immunol. 2016 Aug;169:114-120. doi: 10.1016/j.clim.2016.06.006. Epub 2016 Jun 23.

PMID:
27339331
38.

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.

Bergman P, Piket E, Khademi M, James T, Brundin L, Olsson T, Piehl F, Jagodic M.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e219. doi: 10.1212/NXI.0000000000000219. eCollection 2016 Jun.

39.

No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination.

Lamb F, Ploner A, Fink K, Maeurer M, Bergman P, Piehl F, Weibel D, Sparén P, Dahlström LA.

PLoS One. 2016 Apr 27;11(4):e0154296. doi: 10.1371/journal.pone.0154296. eCollection 2016.

40.

Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function.

Lindblom RP, Aeinehband S, Ström M, Al Nimer F, Sandholm K, Khademi M, Nilsson B, Piehl F, Ekdahl KN.

Clin Immunol. 2016 May;166-167:89-95. doi: 10.1016/j.clim.2016.04.003. Epub 2016 Apr 13.

41.

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F.

Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20.

PMID:
27038238
42.

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J.

Mult Scler. 2017 Jan;23(1):62-71. doi: 10.1177/1352458516639384. Epub 2016 Jul 11.

PMID:
27003946
43.

High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition.

Kierkegaard M, Lundberg IE, Olsson T, Johansson S, Ygberg S, Opava C, Holmqvist LW, Piehl F.

J Neurol Sci. 2016 Mar 15;362:251-7. doi: 10.1016/j.jns.2016.01.063. Epub 2016 Feb 3.

PMID:
26944158
44.

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191. eCollection 2016 Feb.

45.

Rituximab in paediatric onset multiple sclerosis: a case series.

Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A.

J Neurol. 2016 Feb;263(2):322-326. doi: 10.1007/s00415-015-7979-x. Epub 2015 Nov 24.

PMID:
26603152
46.

Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations.

Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJ, Kostera-Pruszczyk A, Szczudlik P, Mckee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L.

Mol Med. 2015 Oct 10. doi: 10.2119/molmed.2015.00232. [Epub ahead of print]

47.

Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response.

Lindblom RP, Berg A, Ström M, Aeinehband S, Dominguez CA, Al Nimer F, Abdelmagid N, Heinig M, Zelano J, Harnesk K, Hübner N, Nilsson B, Ekdahl KN, Diez M, Cullheim S, Piehl F.

J Neuroinflammation. 2015 Oct 26;12:192. doi: 10.1186/s12974-015-0413-6.

48.

Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution.

Johansson K, Cebula M, Rengby O, Dreij K, Carlström KE, Sigmundsson K, Piehl F, Arnér ES.

Antioxid Redox Signal. 2017 Feb 20;26(6):229-246. doi: 10.1089/ars.2015.6419. Epub 2015 Nov 11.

49.

Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.

Aeinehband S, Brenner P, Ståhl S, Bhat M, Fidock MD, Khademi M, Olsson T, Engberg G, Jokinen J, Erhardt S, Piehl F.

Brain Behav Immun. 2016 Jan;51:47-55. doi: 10.1016/j.bbi.2015.07.016. Epub 2015 Jul 17.

PMID:
26189678
50.

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light.

Al Nimer F, Thelin E, Nyström H, Dring AM, Svenningsson A, Piehl F, Nelson DW, Bellander BM.

PLoS One. 2015 Jul 2;10(7):e0132177. doi: 10.1371/journal.pone.0132177. eCollection 2015.

Supplemental Content

Support Center